Published in final edited form as:

Emerg Med Clin North Am. 2018 November ; 36(4): 853–872. doi:10.1016/j.emc.2018.06.012.

Antimicrobial Stewardship in the Emergency Department

Michael Pulia, MD MS¹, Robert Redwood, MD MPH², Larissa May, MD MSPH³

¹Assistant Professor, Director of Emergency Department Antibiotic Stewardship, BerbeeWalsh Department of Emergency Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, United States

²Clinical Adjunct Assistant Professor, Department of Family Medicine, Department of Family Medicine, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI, United States

³Professor, Director of Emergency Department Antibiotic Stewardship, University of California Davis, Sacramento, CA, United States

Keywords

Antibiotics; antimicrobial stewardship; emergency department; quality improvement; infectious diseases

INTRODUCTION

Antimicrobials are unique among all classes of therapeutics in that they decrease in effectiveness over time and in direct relation to the frequency of use.¹ Pathogen resistance develops in response to selective pressure associated with all antibiotic prescribing but is accelerated by inappropriate use. Antimicrobials are critically important medications that affect not only the patient receiving them but also the surrounding community. A substantial increase in global rates of infections related to resistant pathogens, in combination with limited new antimicrobial agents in development, has raised concerns of an impending “post-antibiotic era” with potential catastrophic consequences for human health.²

To address this public health crisis, tremendous efforts have begun to curb the widespread inappropriate use of antimicrobials in both human health and agriculture.^{3–5} Antimicrobial stewardship refers to efforts aimed at optimizing the use of anti-infective medications. There is a substantial body of literature supporting the ability of hospital antimicrobial stewardship programs (ASPs) to reduce costs while also exerting a positive impact on clinical outcomes.⁶ The emergency department (ED) has traditionally been underrepresented as a focus for antimicrobial stewardship efforts. However, policy changes such as the Joint Commission’s antibiotic stewardship accreditation standard (enacted January 1, 2017) and inclusion of

CORRESPONDING AUTHOR: Michael Pulia, 800 University Bay Drive, Suite 310, Madison, WI 53705, mspulia@medicine.wisc.edu.

AUTHOR CONTACT INFORMATION

¹800 University Bay Drive, Suite 300, Madison, WI 53705

²2817 New Pinery Rd, Portage, WI, 53901

³4150 V Street, Suite 2100, Sacramento CA 95817

stewardship quality metrics in the Centers for Medicare & Medicaid Services (CMS) Physician Quality Reporting System^{7,8} will increasingly require ED providers to engage in these efforts.⁹ This review serves as a primer on antimicrobial stewardship tailored for emergency care providers. To achieve this, we present antimicrobial stewardship from both a public health and individual patient safety perspective, review the key domains of stewardship, identify the ED as a critical setting for stewardship efforts, summarize commonly implemented stewardship interventions, and provide stewardship strategies for the most common bacterial infections encountered in the ED

Public Health Impact of Antimicrobial Misuse

Antimicrobial resistance is a phenomenon in which antimicrobials apply selective pressure on pathogens that, in turn, develop defense mechanisms against that antimicrobial agent's mode of action.¹⁰ Antimicrobial resistance has been occurring since the advent of the first antimicrobial agents; however, the speed and severity of this naturally occurring phenomenon is accelerated by the misuse of antimicrobials.¹¹ One recent example of this is the increases in macrolide prescribing throughout the 1990s (+388% in ambulatory care).^{12,13} *Streptococcus pneumoniae* isolates resistance to macrolides rose dramatically during and after this time period, going from 10% in 1994 to 35% in 1995 and to 50% in 2009.¹⁴

From 2000 to 2010, antimicrobial use increased by 36% globally and the trend shows no signs of slowing.¹⁵ Moreover, the US uses a disproportionate amount of antimicrobials per capita, ranking third in the world for total antimicrobial consumption.¹⁵ Antimicrobial resistance is widely regarded as a global epidemic and the conservative estimate for worldwide deaths directly attributable to antimicrobial resistance is 700,000 per year. That figure, however, is projected to swell to 10 million by the year 2050 if current trends continue.¹¹ Unchecked, the cumulative loss of economic output from antimicrobial resistance by 2050 would amount to 20 to 35 trillion US dollars or roughly double the current US gross domestic product.¹¹

Patient Safety Aspects of Antimicrobial Prescribing

Inappropriate and excessive use of antimicrobials remains a major public health threat; however, messaging to healthcare professionals and the public has frequently overlooked the individual patient safety concerns. Recent literature suggests that clinicians who demonstrated increased awareness of potential harm from antibiotics during the clinical decision-making process prescribed fewer antibiotics.¹⁶ The risk of antibiotic-associated adverse events varies by class and the overall incidence may be as high as 20%.^{17,18} These adverse events can range from minor side effects (e.g. diarrhea) to life threatening (e.g. anaphylaxis). Antibiotics are the 2nd most common cause of ED visits for adverse drug events with approximately 1 in 1000 prescriptions resulting in an ED visit.^{18,19} While penicillins and cephalosporins account for the highest volume of adverse drug events encountered in the ED, sulfonamides and clindamycin have the highest rates of adverse events per prescription.¹⁸ Of increasing concern is the rising rate of *Clostridium difficile* Infection (CDI) and resistant bacteria causing Healthcare Associated Infections (HAIs). Antibiotics are the primary risk factor for development of CDI, estimated at nearly half a

million cases and 15,000 attributable deaths each year.²⁰ Furthermore, an estimated 2 million illnesses and 23,000 deaths annually occur from resistant bacteria in the US alone.²¹

The Five Ds of Antimicrobial Stewardship

The application of antimicrobial stewardship to human healthcare has focused on curbing inappropriate utilization. There are “4 Ds” required for optimal antimicrobial prescribing: drug, dose, duration, de-escalation.²² Ideally, the prescriber selects the right drug (e.g. most narrow spectrum), at the right dose (e.g. adjusted for patient renal function), for the right duration (e.g. shortest to successfully treat infection), and considers de-escalation whenever possible (e.g. narrow spectrum based on culture results). A fifth “D” of stewardship, which is perhaps most critical in the context of emergency care, is diagnosis. Prescribing of antibiotics for inappropriate diagnoses (i.e. non-responsive conditions) is prevalent in the emergency department for all common infection types. This includes upper respiratory tract infections (e.g. bronchitis, sinusitis), urinary tract infections (e.g. asymptomatic bacteriuria), and skin and soft tissue infections (e.g. “pseudocellulitis”).^{23–28}

The Emergency Department: A Critical Setting for Antimicrobial Stewardship

The ED is increasingly the central hub of the US healthcare system. Annual ED visits continue to climb each year and according to National Hospital Ambulatory Medical Care Survey data annual US ED visits totaled 136.9 million or 43 per 100 persons in 2015.²⁹ The ED straddles the inpatient and outpatient environment, serving as the primary gateway of entry into the hospital (>80% of all of admissions) and a primary location for acute care encounters (>25%).^{30,31} In fact, a recently published analysis of the US healthcare system concluded that roughly 50% of all medical care occurs in the ED.³²

Infection is one of the most common reasons that patients seek acute, unscheduled care. The Centers for Disease Control and Prevention (CDC) estimate that ~11% (16 million) of annual US ED diagnoses groups were related to infection.³³ Worsening infection also accounts for 11% of short-term readmissions following ED discharge among Medicare recipients.³⁴

Reflecting the infection related visit rates, antimicrobials are one of the most commonly prescribed drug classes in the ED. The CDC estimates that in 2015 US EDs generated over 28 million antibiotic prescriptions.²⁹ Although national data specific to overall ED antibiotic prescribing appropriateness is lacking, a recent single center study in a Veterans Affairs hospital ED identified that 39% of all antimicrobial use was inappropriate.³⁵ This result is consistent with estimated inappropriate antibiotic utilization in both the inpatient and outpatient clinic settings.^{26,36,37}

Cost Impact of Stewardship Interventions

Although not specifically established for the ED setting, inpatient antimicrobial stewardship programs have had substantial cost savings for health systems. A 2016 meta-analysis identified that the majority of stewardship intervention studies demonstrate significant cost savings, through reduced length of stay and drug costs, when included as an outcome.³⁸ Additionally, a 2017 meta-analysis reported significant reductions in colonization and

infection with multidrug-resistance organisms (37-51%) and CDI (32%).³⁹ These benefits are enhanced when paired with infection control programs and CDI rates may be most directly affected by those stewardship programs that restrict use of certain antibiotics.^{39,40} Reductions in difficult to treat HAIs caused by resistant bacteria and CDIs would yield substantial cost savings for US hospitals given the associated increased lengths of stay and substantial penalties applied by CMS related to these conditions.^{41–43}

ANTIMICROBIAL STEWARDSHIP INTERVENTIONS FOR THE EMERGENCY DEPARTMENT

Antimicrobial stewardship interventions can generally be characterized into two broad categories: system-level and provider-level. An alternative method of categorizing stewardship interventions uses the classification of “horizontal” to indicate broad, system level interventions aimed at reducing inappropriate antibiotic prescribing overall (e.g. formulary restrictions) while “vertical” refers to interventions targeting specific antibiotics or infection types.⁴⁴ Naturally, there is some overlap between these classifications as antimicrobial stewardship interventions often involve multiple components and system level care change processes often simultaneously influence behavior at the provider level. In 2016, a joint guideline on implementing antimicrobial stewardship programs was published by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.⁴⁵ This document includes evidence based recommendations for the most commonly utilized stewardship interventions and is an excellent resource for those looking to initiate ED stewardship programs⁴⁶.

OVERVIEW OF SYSTEMS LEVEL INTERVENTIONS

Physician and pharmacist leadership is an essential first step when operationalizing an ED antimicrobial stewardship program. Antimicrobial stewardship efforts should be multidisciplinary, collaborative, patient-centered, and fully supported by hospital administrators. An ED physician champion can serve as liaison between the stewardship program leadership and front line clinicians to facilitate intervention implementation and provision of bidirectional feedback. Successful antimicrobial stewardship in the ED is multifaceted; however, system-level interventions fit broadly into five categories: culture follow-up programs, formulary restrictions, pharmacist initiatives, and antibiograms.

ED Culture Follow up Programs

In the ED setting, all patients diagnosed with an acute infection are discharged home without available culture and susceptibility results. As such, structured culture follow-up programs are one of the first process improvements that should be considered to improve antimicrobial stewardship in the ED. The basic concept of a structured culture follow-up program is that all clinical cultures are to be reviewed by ED staff with attention to any discrepancies between the empirically prescribed antimicrobial therapy and the reported culture and sensitivity data. If a patient is receiving inappropriate or suboptimal antimicrobial therapy, the ED staff (typically a nurse or pharmacist) consults with the emergency physician and adjusts the regimen. If appropriate, a new prescription called to the patient’s outpatient

pharmacy and the patient is contacted and counseled about the culture results and new antimicrobial prescription. Direct contact with the patient is key to effective stewardship, as staff may need to counsel patients about regimen compliance and answer any patient questions. As dedicated ED pharmacists become more commonplace, research suggests that the pharmacist-physician dyad outperforms the nurse-physician in this role.⁴⁷ One study found that having ED pharmacists take over the culture follow-up program saved fifty hours of cumulative emergency physician clinician time per month and decreased infection-related readmissions by 12% with no change in reported adverse drug events.⁴⁸

Emergency Department Formulary Restrictions

As the initial encounter for many episodes of care occurs in the ED, antimicrobial decisions made by emergency care providers often impact subsequent inpatient and outpatient therapy choices. As such, limiting the ED use of certain broad-spectrum antibiotics is one strategy to ensure that the efficacy of these agents will be preserved over time.⁴⁹ A common method for implementing formulary restrictions is to establish a defined ED formulary which excludes specific antibiotics.⁵⁰ Another formulary restriction method is to establish ED criteria for use of certain antimicrobials. In this case, the ED prescriber must give their rationale for the selection of a particular antimicrobial. Typically this is accomplished via computer-physician order entry (CPOE), where the prescriber must select the criteria for use from a pre-populated menu.⁵¹ The decision to restrict an antimicrobial or antimicrobial class is typically based on local resistance patterns and cost considerations when there is a less expensive but equally effective alternative antibiotic. Unintended consequences, such as delays in administration of broad-spectrum therapy in sepsis, should be considered in any formulary restriction policy.

Emergency Department Pharmacist

The presence of a dedicated ED pharmacist is often considered a key component of a collaborative, multidisciplinary ED practice, rather than a stand-alone, measurable intervention.⁵² Nevertheless, multiple studies have demonstrated that ED pharmacists can exert a specific positive impact on antimicrobial stewardship through various roles, including: assisting in the appropriate selection and dosing of empiric antibiotics, enforcing formulary restrictions, adjusting regimens based on organ function/illness severity, structured follow-up on positive cultures, providing education on antimicrobial stewardship, and performing quality improvement projects related to antimicrobial stewardship.^{47,48,53–62}

Emergency Department Antibigrams

An ED antibiogram is “a periodic summary of antimicrobial susceptibilities of local bacterial isolates [from the ED], submitted to the hospital’s clinical microbiology laboratory”.⁶³ It is typically updated annually and used by clinicians and pharmacists to assess ED susceptibility rates, as an aid in selecting empiric antimicrobial therapy, and in monitoring ED resistance trends over time. In practice, many low-volume facilities do not have an ED-specific antibiogram because the minimal number of isolates required to report resistance for a particular organism are not available. Solutions to this problem include constructing a bi-annual antibiogram or pooling data with other local EDs to construct a regional ED antibiogram. Common challenges that occur when first reporting a dedicated

ED antibiogram include difficulty separating ED data from hospital-wide data, difficulty separating screening data from diagnostic data, and difficulty ensuring that the data from admitted patients is not counted twice. Antibiograms should be used to guide ED specific recommendations for empiric treatment of all common bacterial infections.

Overview of Behavioral Interventions

The ED has unique challenges to implementing quality improvement interventions due to frequent interruptions, high-volume care, the need for rapid decisions with limited information, variation in staff over different shifts, and concerns related to patient satisfaction.^{64–66} Furthermore, even though emergency care providers may appreciate the public health implications of growing antimicrobial resistance, changing practice is difficult for a multitude of reasons. In order to ensure each patient gets the right antibiotic at the right dose and for the right duration, or avoiding an antibiotic when not indicated, effective interventions to change prescribing behavior are critically needed.

Traditional educational approaches are not very effective at producing long lasting changes clinical practice. Although education only interventional studies have been published, it is more common to see education included as part of a steward intervention bundle.^{67,68} These typically encompass provision of education on best practice guidelines and provision of associated clinical decision support systems (CDSS). For example, CDSS has been demonstrated to improve ED antibiotic decision making for community acquired pneumonia and uncomplicated urinary tract infections.^{69–71}

Beyond simple education based interventions, evidence from behavioral economics and the psychology decision-making literature suggests that audit and feedback, academic detailing (i.e. one-on-one education), behavioral nudges, and peer comparisons can improve prescribing outcomes.^{72–74} As emergency care providers often rely on heuristics given constraints of time and limited information, behavioral interventions that take into account workflow and decision-making processes have the potential to significantly impact change by targeting specific barriers and facilitators. For example, multifaceted stewardship interventions have been demonstrated to improve ED antibiotic prescribing for pneumonia,^{75–78} urinary tract infections,^{79,80} skin and soft tissue infections,⁸¹ and sepsis.⁸²

Audit and Feedback

Randomized controlled trials of audit and feedback conducted in primary care practices demonstrate that feedback can significantly improve appropriate antibiotic prescribing.^{72,83} One large RCT conducted in this setting utilized a peer comparison feedback intervention that took advantage of social motivation and found that being labeled a top performer or not top performer was an effective means to reduce inappropriate antibiotic prescribing for respiratory tract infections.⁷² However, several studies have demonstrated a reversal of stewardship gains after discontinuation of audit and feedback, suggesting the need for ongoing efforts to achieve sustainability.^{84,85}

Public commitments

Simple interventions that rely on social motivation and accountability to patients and peers such as posters placed in examination rooms and letters with a commitment to avoid potentially harmful antibiotic use has resulted in 20% absolute reduction in prescribing.⁷³ Given the higher acuity and rapid pace of emergency department care relative to clinic settings (i.e. illness or time restrictions preventing patients from reading posters) and absence of treatment areas associated with individual physicians, the effectiveness of physician pledges in this setting is unknown. Emergency care providers may be more likely to be judicious about antibiotic avoidance when they have committed publicly to avoiding patient harm and related materials can be used for patient education.

OVERVIEW OF DIAGNOSTIC INTERVENTIONS

Diagnostic stewardship interventions can be divided into three categories: cultures, organism identification assays, and biomarkers. While traditional cultures are not available to impact prescribing at the point of care, they are a critical component to enhance the downstream tailoring of antibiotic therapy for post ED care in both the inpatient and outpatient setting. Infection-specific cultures (e.g. sputum, urine, wound) may assist in the tailoring or discontinuation of antibiotic therapy but are not routinely advised for uncomplicated urinary tract infections, skin and soft tissue infections, or pneumonia. Additionally, while blood cultures are a core component of sepsis care, routine blood cultures should not be obtained for uncomplicated pneumonias, urinary tract infections (including pyelonephritis), or skin and soft tissue infections due to low clinical utility and the risk of contamination resulting in false positives and unnecessary antibiotic prescribing.^{86–89}

With the emergence of molecular assays that can rapidly identify organisms, such as methicillin resistant *Staphylococcus aureus* (MRSA), there has been increased interest in using these in the ED for stewardship applications. These compliment more traditional organism identification assays such as Group A beta-hemolytic *streptococcus* (GABHS) for pharyngitis and influenza. Finally, procalcitonin (PCT) is a biomarker approved in 2017 by the FDA to assist with antibiotic prescribing decisions for respiratory tract infections.⁹⁰ PCT joins C-reactive protein (CRP) which is the other biomarker that has been tested as an antibiotic stewardship intervention.⁹¹ Each of these interventions will be covered in more detail in their respective condition specific stewardship section.

CONDITION SPECIFIC STEWARDSHIP APPROACHES

Respiratory Tract Infections

Antibiotic prescriptions for non-bacterial respiratory tract infections (e.g. bronchitis, sinusitis, otitis media, non-specific URI) represent the most frequent source of unnecessary antibiotic prescribing in ambulatory care settings.²⁶ While simply avoiding antibiotic prescribing for non-indicated conditions would make a significant impact on stewardship, there are clinical scenarios that involve diagnostic uncertainty, which can also drive overuse. For example, patients with viral respiratory infections (e.g. influenza) may have radiographic infiltrates on chest X-ray which traditionally would prompt a diagnosis of

pneumonia and prescription of antibiotics. One potential solution to this dilemma are Influenza assays, which have been demonstrated in a series of studies to reduce the number of patients presenting to the ED with respiratory tract infection symptoms who receive antibiotic therapy.^{92–95} More broadly, recently commercialized multiplex rapid viral panels have been proposed as a potential solution to improved antibiotic prescribing for respiratory conditions.^{45,96,97} However, several clinical studies, one of which included discharged ED patients, suggest that the broader viral panel results did not significantly change antibiotic prescribing outside of those involving a positive influenza result.^{98,99} It remains to be seen whether incorporating rapid multiplex viral panel results as part of an ED antimicrobial stewardship program could improve their impact.⁴⁵

Procalcitonin is a biomarker upregulated by the presence of bacterial infection and attenuated by viral infections.¹⁰⁰ A 2017 Cochrane review that included data from 32 RCTs concluded that PCT guided antibiotic therapy in the acute care setting is effective in reducing antibiotic prescribing without any adverse effect on patient safety or outcomes.¹⁰¹ On the basis of the available data, PCT was approved by the FDA in 2017 to assist with antibiotic decision making in patients with lower respiratory tract infections (e.g. pneumonia).⁹⁰ The impact of PCT on US ED antibiotic prescribing is unknown as it has not been widely adopted. Epidemiologic data indicate that a bacterial pathogen was identified in less than 15% of patients admitted with pneumonia as diagnosed by the presence of an infiltrate on chest X-ray.¹⁰² This fact suggests a large potential role for PCT in helping to identify pneumonias that are not bacterial in origin.

In cases where the provider has decided to treat suspected pneumonia with antibiotics, stewardship should focus on the selection of optimal empiric therapy. Although recommended for community-acquired pneumonia in the 2007 guideline, increasing national rates of macrolide resistance among *S. pneumonia* isolates means there is a diminishing role for macrolide monotherapy in the treatment of community-acquired pneumonia.^{103,104} Selection of beta-lactam plus doxycycline or azithromycin versus a respiratory fluoroquinolone should be based on patient factors (e.g. comorbidities, potential for medication interactions) and local resistance patterns. Another important area for improved stewardship is to eliminate the use of reflex broad-spectrum antibiotic prescribing for patients meeting the traditional definition of healthcare-associated pneumonia (HCAP): recent admission, residing in a long-term care settings, chemotherapy, or hemodialysis.¹⁰⁵ Due to its poor discriminatory ability for patients at risk for pneumonia due to resistant organisms referred to as PES (*Pseudomonas aeruginosa*, *Enterobacteriaceae* extended-spectrum β -lactamase-positive, and methicillin-resistant *Staphylococcus aureus*),¹⁰⁶ HCAP is no longer considered an appropriate basis for initiation of broad-spectrum antibiotics in ED patients being admitted with pneumonia.^{107,108} A recently published prediction score, drug resistance in pneumonia (DRIP), demonstrated improved diagnostic performance characteristics as compared to HCAP but has not yet been widely validated.¹⁰⁹ Initial studies suggest DRIP can reduce broad-spectrum antibiotic prescribing without adverse clinical outcomes but further research is needed before widespread implementation.^{110–114}

Urinary Tract Infections and Asymptomatic Bacteriuria

Urinary tract infections (UTI) are one of the most common discharge diagnoses made in the ED and the CDC reports that treatment of UTIs in US hospitals could be improved in nearly 40% of cases.³⁶ In order to optimize ED stewardship for UTIs, efforts should focus on improved diagnostic processes (e.g. when to order a urinalysis (UA) and how to correctly interpret it), reduced overtreatment of asymptomatic bacteriuria (ASB), and selection of appropriate empiric antibiotics.

Due to the persistence of myths around the diagnosis of UTI, optimizing the ordering of UAs and urine cultures can have a profound impact on antibiotic prescribing.¹¹⁵ In ideal circumstances, the UA should only be used as a diagnostic test for UTI in the setting of clinical symptoms and suspicion for infection. As it can identify the presence of bacteria in asymptomatic patients, a UA should not be routinely sent as a screening test for UTI.¹¹⁶ Provider-level examples of inappropriate UA ordering include confirming a verbal nursing order for a UA on a patient with no urinary symptoms because the patient is confused, because the sample “looks dirty”, or simply because “the patient had to pee, so I collected a sample doc...should I send it?”.¹¹⁷ Perhaps even more commonplace are the system-level examples of inappropriate UA ordering. One common example is UAs sent on asymptomatic patients because the order is included on a default order set (e.g. abdominal pain, psychiatric clearance, trauma). In either scenario, ordering a UA for a patient with a low pretest probability for UTI puts the ED clinician in a position where the positive predictive value of the UA is greatly diminished and the likelihood of the patient receiving unnecessary antibiotics is greatly increased.

The potential for misdiagnosis and overtreatment is compounded when urine cultures are ordered inappropriately, since the urine culture results are typically reviewed days later, often by a staff member who is not personally familiar with the patient’s signs and symptoms. The two most basic stewardship interventions to reduce ordering of inappropriate urine cultures are to avoid the use of reflex urine cultures and to remove urine cultures from the majority of order sets. Emergency care providers can also combat the ordering of inappropriate urine cultures by implementing two key practice changes. First, they can recognize patient populations that are high-risk for ASB (indwelling foley, long-term care) and avoid sending a UA or urine culture if the patient is not having symptoms. Second, they can add clarity to the situation and improve downstream care by documenting a diagnosis of “Asymptomatic Bacteriuria” if a UA (whether ordered intentionally or unintentionally) shows bacteria for an asymptomatic patient.

The key to understanding why a significant portion of antimicrobials given for UTI are unnecessary hinges on one’s appreciation of what ASB is and what patient populations are at-risk for having ASB. ASB is defined as “an isolation of bacteria in an appropriately collected urine sample from an individual without signs or symptoms referable to a urinary infection”.¹¹⁸ Transient ASB is common in healthy reproductive age women (2-5% prevalence) and even more common during pregnancy (2-11% prevalence).¹¹⁹ These patients may test “positive” one day and then have an unremarkable UA the next day after voiding. If the patient is tested during a period of transient ASB, they are at risk for being prescribed unnecessary antimicrobials.

In certain specialty populations, patients' bladders are colonized with non-pathogenic bacteria, meaning that they will test "positive" at any time. For example, in the long-term care population, the prevalence of ASB varies widely (5-50%) because the presence of ASB typically corresponds to the patient's level of functional impairment, and similarly up to 50% of patients with spinal cord injury or paralysis. Most notably, the prevalence of ASB in patients with indwelling catheters is nearly 100%, meaning that *any* UA sent in this patient population will appear "positive" if the ED clinician does not have a high index of suspicion for ASB.¹¹⁸

Emergency care providers commonly treat ASB, likely, because this practice was standard of care for decades. The logical fallacy is that ASB will progress to pyelonephritis. This pathophysiology was observed in pregnant patients when the urine culture was first developed and the assumption was that the same was true for all patients. This false assumption led to the general treatment of ASB in all patient populations. In fact, according to national infectious disease guidelines, treating ASB is only acceptable in three niche clinical scenarios: pre-urolurgical procedure, immediately post-renal transplant, and *once* in early pregnancy (only if present on two separate urine cultures).¹¹⁶

Another common but controversial example of treating ASB that merits its own discussion is whether or not to order a UA on older adults presenting with altered mental status or functional decline with no urinary symptoms, fever, or clinical instability. The current literature suggests that UTI is not a common cause of altered mental status in the elderly and that the premature incorrect diagnosis of UTI can lead to anchoring bias and prevent the clinician from uncovering the true (often multi-factorial) cause of the altered mental status (e.g. dehydration, hypoxia, polypharmacy, sundowning, sensory impairment, etc).^{120,121} Schulz et al. summarize a reasonable approach to this challenging patient population, asserting that older adults "with acute mental status changes accompanied by bacteriuria and pyuria, without clinical instability or other signs or symptoms of UTI, can reasonably be observed for resolution of confusion for 24–48 hours without antibiotics, while searching for other causes of confusion".¹¹⁵

Another opportunity for stewardship in UTI care involves the selection of appropriate empiric therapy. Ciprofloxacin, once the mainstay of outpatient UTI and pyelonephritis treatment, is rapidly losing its efficacy against *E. coli* with resistance rates averaging 35% in the US.¹²² Therefore it should no longer be considered a universal first line agent for UTI and empiric therapy should be based on local resistance patterns (i.e. ED antibiogram). For most patients with an uncomplicated UTI and normal renal function, we recommend nitrofurantoin or TMP-SMX if local *E. coli* resistance rates are less than 20%.

Catheter Associated UTI

"Catheter associated UTIs" or CAUTIs are a significant source of hospital-acquired infection mortality and thus represent a core component of ED infection prevention and antimicrobial stewardship. One national study estimated that 65% of urinary catheters placed in the ED potentially could have been avoided.¹²³ At the provider-level, clinicians should be aware that urinary catheters should not be placed for incontinence, ease of nursing cares, or urine output measuring.¹²⁴ All catheters placed in the ED should have a plan for removal in

place at the time of initial placement, so that clinical inertia does not result in a catheter being in place longer than is medically necessary. If an ED has a nurse-initiated protocol for catheter placement, the HOUDINI acronym outlines appropriate reasons for placement of a urinary catheter: **H**ematuria, gross; **O**bstruction, urinary; **U**rologic surgery; **D**ecubitus ulcer—open sacral or perineal wound in incontinent patient; **I**nput and output critical for patient management or hemodynamic instability; **N**o code/comfort care/hospice care; **I**mmobility due to physical constraints.¹²⁵

Skin and Soft Tissue Infections

Antimicrobial stewardship considerations in the management of skin and soft tissue infections vary depending on the type of infection. The avoidance of antibiotics following incision and drainage (I&D) of uncomplicated abscesses has been a mainstay of ED antimicrobial stewardship since it was included as part of the American College of Emergency Physician's initial Choosing Wisely® recommendations in 2013.¹²⁶ This guidance was based on a series of RCTs that failed to demonstrate clinical benefit for systemic antibiotics following I&D.¹²⁷

However, two recently published large RCTs did demonstrate a statistically significant reduction in treatment failure and development of recurrent abscesses with TMP-SMX and clindamycin following I&D.^{128,129} These results have prompted some to conclude that antibiotics should become standard of care following I&D of uncomplicated abscesses.¹³⁰ Given the societal ramifications of potential increased bacterial resistance related to routine antibiotic prescribing for the hundreds of thousands of patients with uncomplicated abscesses treated in the US alone each year, a critical analysis of these trial results is necessary.

First, it is important to recognize that the narrow margin of benefit observed for antibiotics in these trials is associated with relatively high numbers needed to treat (NNT) ranging from 7 to 14.^{128,129} Even if applying the results from Daum et al, highest demonstrated margin of benefit observed using a composite definition of treatment failure which included development of future abscesses, approximately 70% of patients do not require antibiotics to successfully resolve their abscess.¹²⁹ Additionally, there were no cases of sepsis or infection related mortality observed among the over 2,000 trial participants, suggesting that withholding antibiotics for uncomplicated abscesses would not compromise patient safety.^{128,129}

Moving forward, emergency care providers should attempt to balance the marginal treatment benefit from post I&D antibiotics with patient safety and public health considerations. One potential solution is to engage in shared decision making which includes discussions about the NNT for this condition and safety risks related to antibiotics. To assist with risk stratification, results from a subgroup analysis of the Talan et al RCT suggest that patients with a history of MRSA or fever are more likely to benefit from antibiotic therapy.¹³¹ Delayed antibiotic prescribing which substantially reduces the number of antibiotic prescriptions filled without increasing complication rates in patients with suspected respiratory tract infections, is another potential strategy.¹³² When providers make a decision to prescribe, the common practice of double coverage for Group A β -hemolytic

streptococcus and MRSA (e.g. cephalixin plus TMP-SMX) should be avoided given clinical cure rates over 80% are achieved with TMP-SMX alone.^{27,133,134} In terms of dosing, clinical cure rates were similar with lower doses of TMP-SMX (160/800 mg twice daily) as compared to double doses (320/1600 mg twice daily).^{128,129} Given increased resistance of *Staphylococcus aureus* isolates to clindamycin in the US, use of this antibiotic in the treatment of abscesses should be guided by local antibiograms.¹³⁵

Another potential solution to enhance antimicrobial stewardship in the management of uncomplicated abscesses is the use of rapid molecular MRSA assays.¹³⁶ One RCT demonstrated that these assays effectively assist emergency care providers in tailoring antibiotic therapy towards the causative bacteria in abscesses while a retrospective study did not show significant improvements due to low uptake of the results by clinicians.^{137,138} The tailoring of therapy is important as antibiotics commonly used to cover MRSA (TMP-SMX and clindamycin) are associated over twice the risk of adverse reaction compared to antibiotics with activity against methicillin sensitive *Staphylococcus aureus* (MSSA) (e.g. cephalixin).¹⁸ The rapid detection of MRSA could also be helpful in risk stratification as patients with MRSA related abscesses were also more likely to benefit from antibiotics in the Talan RCT subgroup analysis.¹³¹

In the case of cellulitis, the primary areas of focus for stewardship should be improving diagnostic accuracy and appropriate antibiotic selection. A recent study published in the dermatology literature concluded that a significant portion (~30%) of ED cellulitis admissions may actually represent non-infectious dermatologic conditions termed pseudocellulitis.²³ Although this was a retrospective single center study, the author correctly suggest emergency care providers should be vigilant for cellulitis mimics such as “venous stasis dermatitis, lymphedema, deep venous thrombosis, gout, and contact dermatitis”.²³ Diagnostic accuracy in the ED can be improved through simple strategies such as passive leg raise to observe abatement of erythema as a sign of non-bacterial etiology and first considering alternative edema causing conditions before making the unlikely diagnosis of bilateral lower extremity cellulitis.¹³⁹ The ‘double coverage’ approach for uncomplicated cellulitis has been evaluated in two RCTs, neither of which observed a reduction in treatment failure with the addition of TMP-SMX to a β -hemolytic streptococcus active antibiotic (e.g cephalixin).^{140,141} Uncomplicated, non-purulent cellulitis should therefore only be treated after careful consideration of potential mimics and be managed with a single antibiotic active against Group A β -hemolytic *Streptococcus*.

Sexually Transmitted Infections

Sexually transmitted infections are the most common notifiable diseases seen in ED settings. There was a nearly 40% increase in the number of STI visits to EDs for the time period 2011-2013 compared to 2008-2010, versus a 2% increase for all diagnoses.¹⁴² Seventeen percent of all STI patients are seen in hospital based EDs, with patients presenting to EDs being more likely to be younger, nonwhite and to have public insurance.¹⁴³

Clinical judgement is often inadequate for diagnosis of STIs, leading to standard practice that involves use of empiric therapy in an effort to prevent public health transmission. Given growing evidence of resistant gonorrhea,¹⁴⁴ overuse of antibiotics to treat STDs is an

imperative topic to address. A randomized controlled trial of rapid STI testing with real time result reporting during the ED visit coupled with specimen self-collection found only 12.9% of patients with symptoms consistent with STI tested positive for chlamydia or gonorrhea. Compared to controls (batched nucleic acid amplification testing), patients in the rapid molecular diagnostic group were significantly less likely to receive unnecessary empiric antibiotic treatment, less likely to report missed antibiotic doses, and more likely to be notified of their results. There were no significant differences in charges or health care utilization measures.¹⁴⁵ These results were mirrored in a recently published quasi-experimental study which also demonstrated the feasibility of rapid STI testing in the ED and observed an associated increase in appropriate antibiotic utilization.¹⁴⁶

SUMMARY/DISCUSSION

Given the increasing role of the ED in the US healthcare system and magnitude of antibiotic use that occurs in this setting, antimicrobial stewardship programs are an important area of focus to improve clinical outcomes, optimize patient safety, and protect antibiotics as a critical public health resource. Opportunities to enhance antimicrobial stewardship are abundant in the ED. Each of the most common infection types (respiratory tract, urinary tract, skin and soft tissue) have aspects of antibiotic prescribing that could be significantly enhanced and we suggest these are starting points for those looking to initiate ED based stewardship quality improvement interventions. The most effective stewardship interventions will involve a bundle approach, building on the strengths of multiple systems and provider level approaches to achieve sustainable improvements in appropriate antibiotic prescribing.

Acknowledgements

Dr. Pulia's effort on this project was supported by grant number K08HS024342 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official view of the Agency for Healthcare Research and Quality.

DISCLOSURE STATEMENT:

Pulia – relevant disclosures: Cembra (advisory board); Cepheid (grant funding, honoraria); Roche Diagnostics (grant funding); Thermo Fisher Scientific (advisory board, consulting)

Redwood – No disclosures

May – relevant disclosures: Cepheid (grant funding, honoraria); Roche Diagnostics (grant funding, advisory board), BioFire (consulting)

REFERENCES

1. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. *Rev Infect Dis.* 1983;5(6):1033–1048. [PubMed: 6318289]
2. WHO | Global action plan on antimicrobial resistance. WHO http://apps.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf?ua=1. Accessed March 2, 2018.
3. Collignon PC, Conly JM, Andremont A, et al. World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine: A Critical Step for Developing Risk Management Strategies to Control Antimicrobial Resistance From Food Animal Production. *Clin Infect Dis.* 2016;63(8):1087–1093. doi:10.1093/cid/ciw475 [PubMed: 27439526]
4. National Strategy to Combat Antibiotic Resistance. <https://www.cdc.gov/drugresistance/federalengagement-in-ar/national-strategy/index.html>. Accessed March 2, 2018.

5. The FAO Action Plan on Antimicrobial Resistance: 2016-2020. United Nations <http://www.fao.org/3/a-i5996e.pdf>. Accessed March 2, 2018.
6. Plachouras D, Hopkins S. Antimicrobial stewardship: we know it works; time to make sure it is in place everywhere. *Cochrane Database Syst Rev*. 2017;2:ED000119. doi:10.1002/14651858.ED000119 [PubMed: 28211043]
7. ACEP PQRS Quality Details: 2016 Regulatory Highlights. <https://www.acep.org/Legislation-and-Avocacy/Federal-Issues/Quality-Issues/2016-Regulatory-Highlights/>. Accessed April 7, 2016.
8. Medicare C for, Baltimore MS 7500 SB, Usa M 2016 Physician Quality Reporting System Measures List. https://www.cms.gov/apps/ama/license.asp?file=/PQRS/downloads/PQRS_2016_Measure_List_01072016.xlsx. Published 3 22, 2018 Accessed March 26, 2018.
9. Joint Commission on Hospital Accreditation. New Antimicrobial Stewardship Standard. *Jt Comm Perspect*. 2016;36(7):1, 3–4, 8.
10. Murray BE, Moellering RC. Patterns and mechanisms of antibiotic resistance. *Med Clin North Am*. 1978;62(5):899–923. [PubMed: 366296]
11. O'Neil J Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations; 2014 https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed February 27, 2018.
12. Neuman MI, Ting SA, Meydani A, Mansbach JM, Camargo CA Jr. National study of antibiotic use in emergency department visits for pneumonia, 1993 through 2008. *Acad Emerg Med*. 2012;19(5):562–568. doi:10.1111/j.1553-2712.2012.01342.x [PubMed: 22594360]
13. McCaig LF, Besser RE, Hughes JM. Antimicrobial-Drug Prescription in Ambulatory Care Settings, United States, 1992–2000. *Emerg Infect Dis*. 2003;9(4):432–437. doi:10.3201/eid0904.020268 [PubMed: 12702222]
14. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. *Emerg Infect Dis*. 2009;15(8):1260–1264. doi:10.3201/eid1508.081187 [PubMed: 19751588]
15. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. *Lancet Infect Dis*. 2014;14(8):742–750. doi:10.1016/S1473-3099(14)70780-7 [PubMed: 25022435]
16. Klein EY, Martinez EM, May L, Saheed M, Reyna V, Broniatowski DA. Categorical Risk Perception Drives Variability in Antibiotic Prescribing in the Emergency Department: A Mixed Methods Observational Study. *J Gen Intern Med*. 2017;32(10):1083–1089. doi:10.1007/s11606-017-4099-6 [PubMed: 28634909]
17. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of Adverse Events With Antibiotic Use in Hospitalized Patients. *JAMA Intern Med*. 2017;177(9):1308–1315. doi:10.1001/jamainternmed.2017.1938 [PubMed: 28604925]
18. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. *Clin Infect Dis*. 2008;47(6):735–743. doi:10.1086/591126 [PubMed: 18694344]
19. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. *JAMA*. 2016;316(20):2115–2125. doi:10.1001/jama.2016.16201 [PubMed: 27893129]
20. Lessa FC, Mu Y, Bamberg WM, et al. Burden of *Clostridium difficile* infection in the United States. *N Engl J Med*. 2015;372(9):825–834. doi:10.1056/NEJMoa1408913 [PubMed: 25714160]
21. U.S. Department of Health and Human Services Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. 2013 <https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf#page=5>. Accessed February 23, 2018.
22. Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. *Expert Opin Pharmacother*. 2008;9(4):561–575. doi:10.1517/14656566.9.4.561 [PubMed: 18312158]
23. Weng QY, Raff AB, Cohen JM, et al. Costs and Consequences Associated With Misdiagnosed Lower Extremity Cellulitis. *JAMA Dermatol*. 2017;153(2):141–146. doi:10.1001/jamadermatol.2016.3816 [PubMed: 27806170]

24. Watson JR, Sánchez PJ, Spencer JD, Cohen DM, Hains DS. Urinary Tract Infection and Antimicrobial Stewardship in the Emergency Department. *Pediatr Emerg Care*. 2018;34(2):93–95. doi:10.1097/PEC.0000000000000688 [PubMed: 26855344]
25. Elshimy G, Mariano V, Joy CM, Kaur P, Singhal M. Are Urinalyses Used Inappropriately in the Diagnosis of Urinary Tract Infections? *Open Forum Infect Dis*. 2017;4(suppl_1):S350–S350. doi:10.1093/ofid/ofx163.842
26. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010–2011. *JAMA*. 2016;315(17):1864–1873. doi:10.1001/jama.2016.4151 [PubMed: 27139059]
27. Pallin DJ, Camargo CA, Schuur JD. Skin infections and antibiotic stewardship: analysis of emergency department prescribing practices, 2007–2010. *West J Emerg Med*. 2014;15(3):282–289. doi:10.5811/westjem.2013.8.18040 [PubMed: 24868305]
28. Gonzales R, Camargo CA, MacKenzie T, et al. Antibiotic treatment of acute respiratory infections in acute care settings. *Acad Emerg Med*. 2006;13(3):288–294. doi:10.1197/j.aem.2005.10.016 [PubMed: 16514122]
29. 2015 NHAMCS Emergency Department summary tables. https://www.cdc.gov/nchs/data/nhamcs/web_tables/2015_ed_web_tables.pdf. Published 2 7, 2018 Accessed March 25, 2018.
30. Gonzalez Morganti K, Bauhoff S, Blanchard JC, et al. The Evolving Roles of Emergency Departments in the United States. https://www.rand.org/content/dam/rand/pubs/research_reports/RR200/RR280/RAND_RR280.pdf. Published 2013 Accessed March 16, 2018.
31. Kocher KE, Dimick JB, Nallamothu BK. Changes in the source of unscheduled hospitalizations in the United States. *Med Care*. 2013;51(8):689–698. doi:10.1097/MLR.0b013e3182992c7b [PubMed: 23752257]
32. Marcozzi D, Carr B, Liferidge A, Baehr N, Browne B. Trends in the Contribution of Emergency Departments to the Provision of Hospital-Associated Health Care in the USA. *Int J Health Serv*. 2018;48(2):267–288. doi:10.1177/0020731417734498 [PubMed: 29039720]
33. U.S. Department of Health and Human Services Centers for Disease Control and Prevention. National Hospital Ambulatory Medical Care Survey: 2014 Emergency Department Summary Tables. 2014 https://www.cdc.gov/nchs/data/nhamcs/web_tables/2014_ed_web_tables.pdf. Accessed February 27, 2018.
34. Gabayan GZ, Sun BC, Asch SM, et al. Qualitative Factors in Patients Who Die Shortly After Emergency Department Discharge. *Acad Emerg Med*. 2013;20(8):778–785. doi:10.1111/acem.12181 [PubMed: 24033620]
35. Timbrook TT, Caffrey AR, Ovalle A, et al. Assessments of Opportunities to Improve Antibiotic Prescribing in an Emergency Department: A Period Prevalence Survey. *Infect Dis Ther*. 2017;6(4):497–505. doi:10.1007/s40121-017-0175-9 [PubMed: 29052109]
36. Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use among hospitalized patients. *MMWR Morb Mortal Wkly Rep*. 2014;63(9):194–200. [PubMed: 24598596]
37. Durkin MJ, Jafarzadeh SR, Hsueh K, et al. Outpatient Antibiotic Prescription Trends in the United States: A National Cohort Study. *Infect Control Amp Hosp Epidemiol*. 2018;1–6. doi:10.1017/ice.2018.26
38. Schuts EC, Hulscher MEJL, Mouton JW, et al. Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. *Lancet Infect Dis*. 2016;16(7):847–856. doi:10.1016/S1473-3099(16)00065-7 [PubMed: 26947617]
39. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and *Clostridium difficile* infection: a systematic review and meta-analysis. *Lancet Infect Dis*. 2017;17(9):990–1001. doi:10.1016/S1473-3099(17)30325-0 [PubMed: 28629876]
40. Feazel LM, Malhotra A, Perencevich EN, Kaboli P, Diekema DJ, Schweizer ML. Effect of antibiotic stewardship programmes on *Clostridium difficile* incidence: a systematic review and meta-analysis. *J Antimicrob Chemother*. 2014;69(7):1748–1754. doi:10.1093/jac/dku046 [PubMed: 24633207]

41. CMS Hospital-Acquired Condition Reduction Program Fiscal Year 2018 Fact Sheet. <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Downloads/FY2018-HAC-Reduction-Program-Fact-Sheet.pdf>. Accessed March 16, 2018.
42. Mitchell BG, Gardner A. Prolongation of length of stay and Clostridium difficile infection: a review of the methods used to examine length of stay due to healthcare associated infections. *Antimicrob Resist Infect Control*. 2012;1(1):14. doi:10.1186/2047-2994-1-14 [PubMed: 22958238]
43. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. *Clin Infect Dis*. 2009;49(8):1175–1184. doi:10.1086/605630 [PubMed: 19739972]
44. Patel PK. Applying the Horizontal and Vertical Paradigm to Antimicrobial Stewardship. *Infect Control Hosp Epidemiol*. 2017;38(5):532–533. doi:10.1017/ice.2017.44 [PubMed: 28421979]
45. Barlam TF, Cosgrove SE, Abbo LM, et al. Executive Summary: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis*. 2016;62(10):1197–1202. doi:10.1093/cid/ciw217 [PubMed: 27118828]
46. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. *Clin Infect Dis*. 2016;62(10):e51–e77. doi:10.1093/cid/ciw118 [PubMed: 27080992]
47. Davis LC, Covey RB, Weston JS, Hu BB, Laine GA. Pharmacist-driven antimicrobial optimization in the emergency department. *Am J Health Syst Pharm*. 2016;73(5 Suppl 1):S49–56. doi:10.2146/sp150036 [PubMed: 26896526]
48. Randolph TC, Parker A, Meyer L, Zeina R. Effect of a pharmacist-managed culture review process on antimicrobial therapy in an emergency department. *Am J Health Syst Pharm*. 2011;68(10):916–919. doi:10.2146/ajhp090552 [PubMed: 21546643]
49. Knox KL, Holmes AH. Regulation of antimicrobial prescribing practices—a strategy for controlling nosocomial antimicrobial resistance. *Int J Infect Dis*. 2002;6:S8–S13. doi:10.1016/S1201-9712(02)90149-9 [PubMed: 12044284]
50. Fagan M, Lindbæk M, Reiso H, Berild D. A simple intervention to reduce inappropriate ciprofloxacin prescribing in the emergency department. *Scand J Infect Dis*. 2014;46(7):481–485. doi:10.3109/00365548.2014.880187 [PubMed: 24552583]
51. Reed EE, Stevenson KB, West JE, Bauer KA, Goff DA. Impact of formulary restriction with prior authorization by an antimicrobial stewardship program. *Virulence*. 2013;4(2):158–162. doi:10.4161/viru.21657 [PubMed: 23154323]
52. ASHP statement on pharmacy services to the emergency department. American Society of Health-System Pharmacists. http://www.ashp.org/s_ashp/docs/files/BP07/New_ED.pdf. Accessed March 27, 2015.
53. Trinh TD, Klinker KP. Antimicrobial Stewardship in the Emergency Department. *Infect Dis Ther*. 2015;4(Suppl 1):39–50. doi:10.1007/s40121-015-0084-8 [PubMed: 26362293]
54. Fairbanks RJ, Hays DP, Webster DF, Spillane LL. Clinical pharmacy services in an emergency department. *Am J Health Syst Pharm*. 2004;61(9):934–937. [PubMed: 15156970]
55. Baker SN, Acquisto NM, Ashley ED, Fairbanks RJ, Beamish SE, Haas CE. Pharmacist-managed antimicrobial stewardship program for patients discharged from the emergency department. *J Pharm Pract*. 2012;25(2):190–194. doi:10.1177/0897190011420160 [PubMed: 22095578]
56. Acquisto NM, Baker SN. Antimicrobial stewardship in the emergency department. *J Pharm Pract*. 2011;24(2):196–202. doi:10.1177/0897190011400555 [PubMed: 21712214]
57. DeFrates SR, Weant KA, Seamon JP, Shirakbari A, Baker SN. Emergency pharmacist impact on health care-associated pneumonia empiric therapy. *J Pharm Pr*. 2013;26(2):125–130. doi:10.1177/0897190012451933
58. Weant KA, Baker SN. Emergency medicine pharmacists and sepsis management. *J Pharm Pract*. 2013;26(4):401–405. doi:10.1177/0897190012467211 [PubMed: 23204144]

59. DeWitt KM, Weiss SJ, Rankin S, Ernst A, Sarangarm P. Impact of an emergency medicine pharmacist on antibiotic dosing adjustment. *Am J Emerg Med*. 2016;34(6):980–984. doi:10.1016/j.ajem.2016.02.004 [PubMed: 26947363]
60. Lingenfelter E, Drapkin Z, Fritz K, Youngquist S, Madsen T, Fix M. ED pharmacist monitoring of provider antibiotic selection aids appropriate treatment for outpatient UTI. *Am J Emerg Med*. 2016;34(8):1600–1603. doi:10.1016/j.ajem.2016.05.076 [PubMed: 27306262]
61. Bailey AM, Stephan M, Weant KA, Justice SB. Dosing of Appropriate Antibiotics and Time to Administration of First Doses in the Pediatric Emergency Department. *J Pediatr Pharmacol Ther*. 2015;20(4):309–315. doi:10.5863/1551-6776-20.4.309 [PubMed: 26380571]
62. Hunt A, Nakajima S, Hall Zimmerman L, Patel M. Impact of prospective verification of intravenous antibiotics in an ED. *Am J Emerg Med*. 2016;34(12):2392–2396. doi:10.1016/j.ajem.2016.09.004 [PubMed: 27641249]
63. Joshi S Hospital antibiogram: a necessity. *Indian J Med Microbiol*. 2010;28(4):277–280. doi:10.4103/0255-0857.71802 [PubMed: 20966554]
64. Chisholm CD, Collison EK, Nelson DR, Cordell WH. Emergency Department Workplace Interruptions Are Emergency Physicians “Interrupt-driven” and “Multitasking”? *Acad Emerg Med*. 2000;7(11):1239–1243. doi:10.1111/j.1553-2712.2000.tb00469.x [PubMed: 11073472]
65. IFEM Framework for Quality and Safety in the Emergency Department. <https://www.ifem.cc/wp-content/uploads/2016/03/Framework-for-Quality-and-Safety-in-the-Emergency-Department-2012.doc.pdf>. Accessed June 15, 2018.
66. Chisholm CD, Weaver CS, Whemmouth L, Giles B. A Task Analysis of Emergency Physician Activities in Academic and Community Settings. *Ann Emerg Med*. 2011;58(2):117–122. doi:10.1016/j.annemergmed.2010.11.026 [PubMed: 21276642]
67. Klein LE, Charache P, Johannes RS. Effect of physician tutorials on prescribing patterns of graduate physicians. *J Med Educ*. 1981;56(6):504–511. [PubMed: 7346637]
68. Metlay JP, Camargo CA, MacKenzie T, et al. Cluster-randomized trial to improve antibiotic use for adults with acute respiratory infections treated in emergency departments. *Ann Emerg Med*. 2007;50(3):221–230. doi:10.1016/j.annemergmed.2007.03.022 [PubMed: 17509729]
69. Buising KL, Thursky KA, Black JF, et al. Improving antibiotic prescribing for adults with community acquired pneumonia: Does a computerised decision support system achieve more than academic detailing alone? – a time series analysis. *BMC Med Inform Decis Mak*. 2008;8(1):35. doi:10.1186/1472-6947-8-35 [PubMed: 18667084]
70. Demonchy E, Dufour J-C, Gaudart J, et al. Impact of a computerized decision support system on compliance with guidelines on antibiotics prescribed for urinary tract infections in emergency departments: a multicentre prospective before-and-after controlled interventional study. *J Antimicrob Chemother*. 2014;69(10):2857–2863. doi:10.1093/jac/dku191 [PubMed: 24898019]
71. Dean NC, Jones BE, Jones JP, et al. Impact of an Electronic Clinical Decision Support Tool for Emergency Department Patients With Pneumonia. *Ann Emerg Med*. 2015;66(5):511–520. doi:10.1016/j.annemergmed.2015.02.003 [PubMed: 25725592]
72. Meeker D, Linder JA, Fox CR, et al. Effect of behavioral interventions on inappropriate antibiotic prescribing among primary care practices: A randomized clinical trial. *JAMA*. 2016;315(6):562–570. doi:10.1001/jama.2016.0275 [PubMed: 26864410]
73. Meeker D, Knight TK, Friedberg MW, et al. Nudging guideline-concordant antibiotic prescribing: a randomized clinical trial. *JAMA Intern Med*. 2014;174(3):425–431. doi:10.1001/jamainternmed.2013.14191 [PubMed: 24474434]
74. Spellberg B Antibiotic judo: working gently with prescriber psychology to overcome inappropriate use. *JAMA Intern Med*. 2014;174(3):432–433. doi:10.1001/jamainternmed.2013.14019 [PubMed: 24474306]
75. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. *JAMA*. 2000;283(6):749–755. doi:10.1001/jama.283.6.749 [PubMed: 10683053]
76. Ambroggio L, Thomson J, Murtagh Kurowski E, et al. Quality Improvement Methods Increase Appropriate Antibiotic Prescribing for Childhood Pneumonia. *Pediatrics*. 2013;131(5):e1623–e1631. doi:10.1542/peds.2012-2635 [PubMed: 23589819]

77. Ostrowsky B, Sharma S, DeFino M, et al. Antimicrobial stewardship and automated pharmacy technology improve antibiotic appropriateness for community-acquired pneumonia. *Infect Control Hosp Epidemiol.* 2013;34(6):566–572. doi:10.1086/670623 [PubMed: 23651886]
78. Julian-Jimenez A, Palomo de los Reyes MJ, Parejo Miguez R, Lain-Teres N, Cuenca-Boy R, Lozano-Ancin A. Improved management of community-acquired pneumonia in the emergency department. *Arch Bronconeumol.* 2013;49(6):230–240. doi:10.1016/j.arbres.2012.12.008 [PubMed: 23477946]
79. Hecker MT, Fox CJ, Son AH, et al. Effect of a stewardship intervention on adherence to uncomplicated cystitis and pyelonephritis guidelines in an emergency department setting. *PloS One.* 2014;9(2):e87899. doi:10.1371/journal.pone.0087899 [PubMed: 24498394]
80. Percival KM, Valenti KM, Schmittling SE, Strader BD, Lopez RR, Bergman SJ. Impact of an antimicrobial stewardship intervention on urinary tract infection treatment in the ED. *Am J Emerg Med.* 2015;33(9):1129–1133. doi:10.1016/j.ajem.2015.04.067 [PubMed: 26027885]
81. Trajano R, Ondak S, Tancredi D, et al. Emergency Department Specific Antimicrobial Stewardship Intervention Reduces Antibiotic Duration and Selection for Discharged Adult and Pediatric Patients with Skin and Soft-tissue infections. *Open Forum Infect Dis.* 2017;4(Suppl 1):S274. doi:10.1093/ofid/ofx163.610
82. Francis M, Rich T, Williamson T, Peterson D. Effect of an emergency department sepsis protocol on time to antibiotics in severe sepsis. *CJEM.* 2010;12(4):303–310. [PubMed: 20650022]
83. Gerber JS, Prasad PA, Fiks AG, et al. Effect of an Outpatient Antimicrobial Stewardship Intervention on Broad-Spectrum Antibiotic Prescribing by Primary Care Pediatricians: A Randomized Trial. *JAMA.* 2013;309(22):2345–2352. doi:10.1001/jama.2013.6287 [PubMed: 23757082]
84. Linder JA, Meeker D, Fox CR, et al. Effects of Behavioral Interventions on Inappropriate Antibiotic Prescribing in Primary Care 12 Months After Stopping Interventions. *JAMA.* 2017;318(14):1391–1392. doi:10.1001/jama.2017.11152 [PubMed: 29049577]
85. Gerber JS, Prasad PA, Fiks AG, et al. Durability of Benefits of an Outpatient Antimicrobial Stewardship Intervention After Discontinuation of Audit and Feedback. *JAMA.* 2014;312(23):2569–2570. doi:10.1001/jama.2014.14042 [PubMed: 25317759]
86. Makam AN, Auerbach AD, Steinman MA. Blood Culture Use in the Emergency Department in Patients Hospitalized for Community-Acquired Pneumonia. *JAMA Intern Med.* 2014;174(5):803–806. doi:10.1001/jamainternmed.2013.13808 [PubMed: 24614986]
87. Mills AM, Chen EH. Are blood cultures necessary in adults with cellulitis? *Ann Emerg Med.* 2005;45(5):548–549. doi:10.1016/j.annemergmed.2004.11.006 [PubMed: 15855955]
88. Velasco M, Martínez JA, Moreno-Martínez A, et al. Blood Cultures for Women with Uncomplicated Acute Pyelonephritis: Are They Necessary? *Clin Infect Dis.* 2003;37(8):1127–1130. doi:10.1086/378291 [PubMed: 14523779]
89. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. *Crit Care Med.* 2013;41(2):580–637. doi:10.1097/CCM.0b013e31827e83af [PubMed: 23353941]
90. Voelker R Test Aids Antibiotic Decisions. *JAMA.* 2017;317(13):1308–1308. doi:10.1001/jama.2017.2685
91. Gonzales R, Aagaard EM, Camargo CA Jr, et al. C-reactive protein testing does not decrease antibiotic use for acute cough illness when compared to a clinical algorithm. *J Emerg Med.* 2011;41(1):1–7. doi:10.1016/j.jemermed.2008.06.021 [PubMed: 19095403]
92. Blaschke AJ, Shapiro DJ, Pavia AT, et al. A National Study of the Impact of Rapid Influenza Testing on Clinical Care in the Emergency Department. *J Pediatr Infect Soc.* 2014;3(2):112–118. doi:10.1093/jpids/pit071
93. Noyola DE, Demmler GJ. Effect of rapid diagnosis on management of influenza A infections. *Pediatr Infect Dis J.* 2000;19(4):303–307. [PubMed: 10783019]
94. Esposito S, Marchisio P, Morelli P, Crovari P, Principi N. Effect of a rapid influenza diagnosis. *Arch Dis Child.* 2003;88(6):525–526. [PubMed: 12765923]
95. Bonner AB, Monroe KW, Talley LI, Klasner AE, Kimberlin DW. Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency

- department: results of a randomized, prospective, controlled trial. *Pediatrics*. 2003;112(2):363–367. [PubMed: 12897288]
96. Rogers BB, Shankar P, Jerris RC, et al. Impact of a rapid respiratory panel test on patient outcomes. *Arch Pathol Lab Med*. 2015;139(5):636–641. doi:10.5858/arpa.2014-0257-OA [PubMed: 25152311]
 97. Huang H-S, Tsai C-L, Chang J, Hsu T-C, Lin S, Lee C-C. Multiplex PCR system for the rapid diagnosis of respiratory virus infection: systematic review and meta-analysis. *Clin Microbiol Infect*. 2017; Epub ahead of print]. doi:10.1016/j.cmi.2017.11.018
 98. Green DA, Hitoaliaj L, Kotansky B, Campbell SM, Peaper DR. Clinical Utility of On-Demand Multiplex Respiratory Pathogen Testing among Adult Outpatients. *J Clin Microbiol*. 2016;54(12):2950–2955. doi:10.1128/JCM.01579-16 [PubMed: 27654334]
 99. Semret M, Schiller I, Jardin BA, et al. Multiplex Respiratory Virus Testing for Antimicrobial Stewardship: A Prospective Assessment of Antimicrobial Use and Clinical Outcomes Among Hospitalized Adults. *J Infect Dis*. 2017;216(8):936–944. doi:10.1093/infdis/jix288 [PubMed: 29149338]
 100. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet*. 1993;341(8844):515–518. doi:10.1016/0140-6736(93)90277-N
 101. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev*. 2017;10:CD007498. doi:10.1002/14651858.CD007498.pub3 [PubMed: 29025194]
 102. Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. *N Engl J Med*. 2015;373(5):415–427. doi:10.1056/NEJMoal500245 [PubMed: 26172429]
 103. Niederman MS. Macrolide-Resistant *Pneumococcus* in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy? *Am J Respir Crit Care Med*. 2015;191(11):1216–1217. doi:10.1164/rccm.201504-0701ED [PubMed: 26029831]
 104. ResistanceMap. <https://resistancemap.cddep.org/>. Accessed October 27, 2017.
 105. Abrahamian FM, DeBlieux PM, Emerman CL, et al. Health care-associated pneumonia: identification and initial management in the ED. *Am J Emerg Med*. 2008;26(6):1–11. doi:<http://dx.doi.org.ezproxy.library.wisc.edu/10.1016/j.ajem.2008.03.015>
 106. Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. *Ann Am Thorac Soc*. 2015;12(2):153–160. doi:10.1513/AnnalsATS.201407-305OC [PubMed: 25521229]
 107. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-Associated Pneumonia Does Not Accurately Identify Potentially Resistant Pathogens: A Systematic Review and Meta-Analysis. *Clin Infect Dis*. 2014;58(3):330–339. [PubMed: 24270053]
 108. Dean NC, Webb BJ. Health Care–Associated Pneumonia is Mostly Dead. Long Live the Acronym PES? *Ann Am Thorac Soc*. 2015;12(2):239–240. doi:10.1513/AnnalsATS.201501-002ED [PubMed: 25706489]
 109. Webb BJ, Dascomb K, Stenehjem E, et al. Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score. *Antimicrob Agents Chemother*. 2016;60(5):2652–2663. doi:10.1128/AAC.03071-15 [PubMed: 26856838]
 110. Self WH, Wunderink RG, Williams DJ, Barrett TW, Baughman AH, Grijalva CG. Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia. *Acad Emerg Med*. 2015;22(6):730–740. doi:10.1111/acem.12672 [PubMed: 25996620]
 111. Webb BJ, Dascomb K, Stenehjem E, Dean N. Predicting risk of drug-resistant organisms in pneumonia: moving beyond the HCAP model. *Respir Med*. 2015;109(1):1–10. doi:10.1016/j.rmed.2014.10.017 [PubMed: 25468412]
 112. Webb BJ, Stenehjem E, Dascomb K, Metersky M, Vikram HR, Dean NC. Reply to Babbal et al., “Application of the DRIP Score at a Veterans Affairs Hospital.” *Antimicrob Agents Chemother*. 2018;62(3):e02337–17. doi:10.1128/AAC.02337-17 [PubMed: 29475893]

113. Babbel D, Sutton J, Rose R, Yarbrough P, Spivak ES. Application of the DRIP Score at a Veterans Affairs Hospital. *Antimicrob Agents Chemother*. 2018;62(3):e02277–17. doi:10.1128/AAC.02277-17 [PubMed: 29475891]
114. Farkas A, Sassine J, Mathew JP, Stavropoulos C, Stern R, Mckinley G. Outcomes associated with the use of a revised risk assessment strategy to predict antibiotic resistance in community-onset pneumonia: a stewardship perspective. *J Antimicrob Chemother*. 2018;[Epub ahead of print]. doi:10.1093/jac/dky202
115. Schulz L, Hoffman RJ, Pothof J, Fox B. Top Ten Myths Regarding the Diagnosis and Treatment of Urinary Tract Infections. *J Emerg Med*. 2016;51(1):25–30. doi:10.1016/j.jemermed.2016.02.009 [PubMed: 27066953]
116. Nicolle LE. Asymptomatic bacteriuria: when to screen and when to treat. *Infect Dis Clin North Am*. 2003;17(2):367–394. [PubMed: 12848475]
117. Redwood R, Knobloch MJ, Pellegrini DC, Ziegler MJ, Pulia M, Safdar N. Reducing unnecessary culturing: a systems approach to evaluating urine culture ordering and collection practices among nurses in two acute care settings. *Antimicrob Resist Infect Control*. 2018;7:4. doi:10.1186/s13756-017-0278-9 [PubMed: 29340148]
118. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2005;40(5):643–654. doi:10.1086/427507
119. Hooton TM, Scholes D, Stapleton AE, et al. A prospective study of asymptomatic bacteriuria in sexually active young women. *N Engl J Med*. 2000;343(14):992–997. doi:10.1056/NEJM200010053431402 [PubMed: 11018165]
120. Tambyah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. *Arch Intern Med*. 2000;160(5):678–682. [PubMed: 10724054]
121. Beveridge LA, Davey PG, Phillips G, McMurdo ME. Optimal management of urinary tract infections in older people. *Clin Interv Aging*. 2011;6:173–180. doi:10.2147/CIA.S13423 [PubMed: 21753872]
122. Fasugba O, Gardner A, Mitchell BG, Mnatzaganian G. Ciprofloxacin resistance in community- and hospital-acquired *Escherichia coli* urinary tract infections: a systematic review and meta-analysis of observational studies. *BMC Infect Dis*. 2015;15:545. doi:10.1186/s12879-015-1282-4 [PubMed: 26607324]
123. Schuur JD, Chambers JG, Hou PC. Urinary catheter use and appropriateness in U.S. emergency departments, 1995-2010. *Acad Emerg Med*. 2014;21(3):292–300. doi:10.1111/acem.12334 [PubMed: 24628754]
124. Carter EJ, Pallin DJ, Mandel L, Sinnette C, Schuur JD. Emergency Department Catheter-Associated Urinary Tract Infection Prevention: Multisite Qualitative Study of Perceived Risks and Implemented Strategies. *Infect Control Hosp Epidemiol*. 2016;37(02):156–162. doi:10.1017/ice.2015.267 [PubMed: 26526870]
125. Adams D, Bucior H, Day G, Rimmer J-A. HOUDINI: make that urinary catheter disappear – nurse-led protocol. *J Infect Prev*. 2012;13(2):44–46. doi:10.1177/1757177412436818
126. ACEP Joins Choosing Wisely Campaign. ACEP Now. <http://www.acepnow.com/article/acep-joins-choosing-wisely-campaign/>. Accessed December 19, 2017.
127. Singer AJ, Thode HC Jr. Systemic antibiotics after incision and drainage of simple abscesses: a meta-analysis. *Emerg Med J*. 2014;31(7):576–578. doi:10.1136/emmermed-2013-202571 [PubMed: 23686731]
128. Talan DA, Mower WR, Krishnadasan A, et al. Trimethoprim-Sulfamethoxazole versus Placebo for Uncomplicated Skin Abscess. *N Engl J Med*. 2016;374(9):823–832. doi:10.1056/NEJMoa1507476 [PubMed: 26962903]
129. Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. *N Engl J Med*. 2017;376(26):2545–2555. doi:10.1056/NEJMoa1607033 [PubMed: 28657870]

130. Vermandere M, Aertgeerts B, Agoritsas T, et al. Antibiotics after incision and drainage for uncomplicated skin abscesses: a clinical practice guideline. *BMJ*. 2018;360:k243. doi:10.1136/bmj.k243 [PubMed: 29437651]
131. Talan DA, Moran GJ, Krishnadasan A, et al. Subgroup Analysis of Antibiotic Treatment for Skin Abscesses. *Ann Emerg Med*. 2018;71(1):21–30. doi:10.1016/j.annemergmed.2017.07.483 [PubMed: 28987525]
132. Spurling GK, Del Mar CB, Dooley L, Foxlee R, Farley R. Delayed antibiotic prescriptions for respiratory infections. *Cochrane Database Syst Rev*. 2017;9:CD004417. doi:10.1002/14651858.CD004417.pub5 [PubMed: 28881007]
133. Schmitz G, Goodwin T, Singer A, et al. The Treatment of Cutaneous Abscesses: Comparison of Emergency Medicine Providers' Practice Patterns. *West J Emerg Med*. 2013;14(1):23–28. doi:10.5811/westjem.2011.9.6856 [PubMed: 23447753]
134. May L, Harter K, Yadav K, et al. Practice patterns and management strategies for purulent skin and soft-tissue infections in an urban academic ED. *Am J Emerg Med*. 2012;30(2):302–310. doi:10.1016/j.ajem.2010.11.033 [PubMed: 21277138]
135. Sutter DE, Milburn E, Chukwuma U, Dzialowy N, Maranich AM, Hospenthal DR. Changing Susceptibility of *Staphylococcus aureus* in a US Pediatric Population. *Pediatrics*. 2016;137(4). doi:10.1542/peds.2015-3099
136. Pulia M, Calderone M, Hansen B, et al. Feasibility of rapid polymerase chain reaction for detection of methicillin-resistant *Staphylococcus aureus* colonization among emergency department patients with abscesses. *Open Access Emerg Med*. 2013;5:17–22. doi:10.2147/OAEM.S50226 [PubMed: 27147869]
137. May LS, Rothman RE, Miller LG, et al. A Randomized Clinical Trial Comparing Use of Rapid Molecular Testing for *Staphylococcus aureus* for Patients With Cutaneous Abscesses in the Emergency Department With Standard of Care. *Infect Control Hosp Epidemiol*. 2015;36(12):1423–1430. doi:10.1017/ice.2015.202 [PubMed: 26306996]
138. Terp S, Krishnadasan A, Bowen W, et al. Introduction of Rapid Methicillin-Resistant *Staphylococcus aureus* Polymerase Chain Reaction Testing and Antibiotic Selection Among Hospitalized Patients With Purulent Skin Infections. *Clin Infect Dis*. 2014;58(8):e129–e132. doi:10.1093/cid/ciu039 [PubMed: 24457337]
139. McCreary EK, Heim ME, Schulz LT, Hoffman R, Pothof J, Fox B. Top 10 Myths Regarding the Diagnosis and Treatment of Cellulitis. *J Emerg Med*. 2017;53(4):485–492. doi:10.1016/j.jemermed.2017.05.007 [PubMed: 28684060]
140. Moran GJ, Krishnadasan A, Mower WR, et al. Effect of Cephalexin Plus Trimethoprim-Sulfamethoxazole vs Cephalexin Alone on Clinical Cure of Uncomplicated Cellulitis. *JAMA*. 2017;317(20):2088–2096. doi:10.1001/jama.2017.5653 [PubMed: 28535235]
141. Pallin DJ, Binder WD, Allen MB, et al. Comparative Effectiveness of Cephalexin Plus Trimethoprim-Sulfamethoxazole Versus Cephalexin Alone for Treatment of Uncomplicated Cellulitis: A Randomized Controlled Trial. *Clin Infect Dis*. 2013;56(12):1754–1762. doi:10.1093/cid/cit122 [PubMed: 23457080]
142. Pearson WS, Peterman TA, Gift TL. An increase in sexually transmitted infections seen in US emergency departments. *Prev Med*. 2017;100:143–144. doi:10.1016/j.ypmed.2017.04.028 [PubMed: 28455221]
143. Ware CE, Ajabnoor Y, Mullins PM, Mazer-Amirshahi M, Pines JM, May L. A retrospective cross-sectional study of patients treated in US EDs and ambulatory care clinics with sexually transmitted infections from 2001 to 2010. *Am J Emerg Med*. 2016;34(9):1808–1811. doi:10.1016/j.ajem.2016.06.039 [PubMed: 27329297]
144. Kirkcaldy RD, Harvey A, Papp JR, et al. *Neisseria gonorrhoeae* Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. *Morb Mortal Wkly Rep Surveill Summ*. 2016;65(7):1–19. doi:10.15585/mmwr.ss6507a1
145. May L, Ware CE, Jordan JA, et al. A Randomized Controlled Trial Comparing the Treatment of Patients Tested for Chlamydia and Gonorrhea After a Rapid Polymerase Chain Reaction Test Versus Standard of Care Testing. *Sex Transm Dis*. 2016;43(5):290–295. doi:10.1097/olq.0000000000000438 [PubMed: 27100764]

146. Rivard KR, Dumkow LE, Draper HM, Brandt KL, Whalen DW, Egwuatu NE. Impact of rapid diagnostic testing for chlamydia and gonorrhea on appropriate antimicrobial utilization in the emergency department. *Diagn Microbiol Infect Dis*. 2017;87(2):175–179. doi:10.1016/j.diagmicrobio.2016.10.019 [PubMed: 27836225]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

KEY POINTS

- The emergency department is a critical setting for antimicrobial stewardship efforts given the frequency of infectious disease encounters and its major role in hospital admissions and acute care outpatient encounters.
- Institutional support, especially for a physician champion, is critical for the success of any emergency department based antimicrobial stewardship intervention.
- The biomarker procalcitonin and influenza assays are effective means to differentiate viral from bacteria causes of respiratory tract infections and thereby safely reduce unnecessary antibiotic prescribing.
- Emergency department stewardship efforts for urinary tract infections should focus on avoiding routine screening urinalyses for patients without urinary complaints and reducing treatment of asymptomatic bacteriuria.
- Clinical cure rates for uncomplicated abscesses are marginally improved with antibiotics following incision and drainage. The decision to prescribe antibiotics should involve shared decision making which includes discussion of the risk/benefit ratio.
- High quality evidence suggests that uncomplicated cellulitis antibiotic regimens do not need to include coverage for methicillin resistant *Staphylococcus aureus*.

SYNOPSIS

The emergency department (ED) is the hub of the US healthcare system, serving as the primary source of hospital admissions and accounting for nearly 1 in 4 acute care outpatient visits. Acute infectious diseases are frequently encountered in the ED setting, making this a critical setting for antimicrobial stewardship efforts. Systems level and behavioral stewardship interventions have demonstrated success in the ED setting but successful implementation depends on institutional support and the presence of a physician champion. Antimicrobial stewardship efforts in the ED should target high impact areas: (1) Antibiotic prescribing for non-indicated respiratory tract conditions such as bronchitis and sinusitis; (2) Overtreatment of asymptomatic bacteriuria; (3) Using two antibiotics (double coverage) for uncomplicated cases of cellulitis or abscess.